Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FAP Clear all
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions
patisiran
Drug
Lead sponsor
Austin Neuromuscular Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Transthyretin Amyloidosis
Interventions
I 124-Evuzamitide
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 105 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Familial Amyloid Polyneuropathy
Interventions
Fx-1006A, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced May 22, 2026, 12:13 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Personalized surveillance and intervention protocol
Procedure
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Hereditary Transthyretin Amyloidosis With Polyneuropthy
Interventions
TEGSEDI
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rosedale, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Amyloidosis, Transthyretin Amyloidosis
Interventions
124I-Evuzamitide
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Placebo, Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
NNC6019-0001
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced May 22, 2026, 12:13 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Personalized surveillance and intervention protocol
Procedure
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Celecoxib, Colonoscopy Biopsy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Amyloidosis
Interventions
Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Interventions
Erlotinib, Erlotinib Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Interventions
Inotersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 82 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
NTLA-2001, Placebo
Biological · Drug
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced May 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Vutrisiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
La Mesa, California • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
Interventions
[Ga-68]-PNT6555, [Lu-177]-PNT6555
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Curcumin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced May 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Encapsulated Rapamycin (eRapa)
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
124I-AT03
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced May 22, 2026, 12:13 AM EDT
Terminated No phase listed Observational Results available
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
Celecoxib, Routine Medical Care
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced May 22, 2026, 12:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Map Syndrome, Lynch Syndrome, Hnpcc, Colorectal Cancer
Interventions
Epi proColon Testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced May 22, 2026, 12:13 AM EDT